Current Grants and Contracts

Clinical and Economic Outcomes of a Digital Health Offering in a Patient Population with Cardiovascular and Metabolic Chronic Disease

Principal investigator: Haesuk Park
Study period: 06/01/2016-12/31/2017
Funding agency: Proteus Digital Health
This project will evaluate the real-world impact of a digital health offering on adherence, clinical and economic outcomes, and healthcare utilization at Barton Health.

Medicaid Drug Therapy Management Program for Behavioral Health – Use of antipsychotics in preschoolers

Principal investigators: Almut Winterstein and Yu-Jung “Jenny” Wei
Study Period: 11/1/2016-6/30/2017
Funding Agency: Florida Agency for Healthcare Administration through a subcontract with the University of Florida Florida Medicaid Drug Therapy Management Program for Behavioral Health
This study aims to determine psychotropic drug utilization trajectories in preschoolers with antipsychotics over the past 15 years in Florida, as well as effects of antipsychotic exposure during early childhood on somatic side effects, including type 2 diabetes and tardive dyskinesia.

Pharmacological Management of Pain in Alzheimer’s Disease and Related Dementia

Principal investigator: Yu-Jung “Jenny” Wei
Study period: 07/01/2016 – 06/30/2017
Funding agency: UF College of Pharmacy PROSPER Research Enhancement Award
This study aims to determine the quality of pain management, examine factors associated with the pain management quality and investigate the extent to which pain control is associated with a decreased risk for mental health disorders.

Long-term outcomes in Florida Medicaid beneficiaries who received antipsychotics under the prior authorization programs

Principal investigator: Yu-Jung “Jenny” Wei
Study period: 03/01/2016 – 06/30/2016
Funding agency: Subcontract with University of South Florida
This project aims to answer 1) what types and at what rate children included in the antipsychotic prior authorization program develop physical outcomes; and 2) what differences between risks for physical outcomes exist across age groups and race/ethnic groups.

Science of Global Prostate Cancer Disparities

Principal investigator: Rich Segal (Folake Odedina: Co-Principal Investigator)
Study period: March 2016 to December 2016
Funding agency: NIH/NCI
Conference to study global prostate cancer with emphasis on designing research collaborations among patient advocates, researchers, clinicians and NCI program officers.

Improving Medication Related Outcomes by Having Community Health Workers Collaborate with Pharmacist

Principal investigator: Rich Segal (Folake Odedina: Co-Principal Investigator)
Study period:
Funding agency: DOH and CDC
This Project focuses on evaluating a new practice models focusing on collaborations of community health workers and pharmacists to improve therapeutic outcomes among poorly controlled patients with hypertension and/or diabetes.

Effects of Medicare Dialysis Quality Incentive Program on Anemia Care

Principal investigator: Haesuk Park
Study period: 08/01/2016-07/31/2017
Funding agency: UF College of Pharmacy PROSPER Research Enhancement Award
This project will investigate the effects of end-stage renal disease payment reforms (prospective payment system and quality incentive program) on anemia care in Medicare beneficiaries on dialysis..

Systematic Review of Geographic Differences in Cancer Outcomes

Principal investigator: Hong Xiao
Study period: 1/1/2016-12/31/2016
Funding agency: UF College of Pharmacy PROSPER Research Award
This project will review current literature of spatial analyses in prostate and breast cancer outcomes including diagnosis, treatment and survival. Geographic differences, if any, in these outcomes will be highlighted and potential reasons for such differences will be investigated in future research.

Evaluating changes in order sets for inpatient pain management

Principal investigator: Almut G. Winterstein
Study period: 1/1/2016 – 6/30/2016
Funding agency: UF Health Shands Endowment Fund
This study will evaluate the effectiveness and safety of newly implemented explicit opioid titration protocols at UF Health Shands.

Real-time risk stratification of hypo- and hyperglycemia to enhance glucose management outcomes in hospitals

HHSF-223-2015-10118C [FDABAA-15-00121]
Principal investigator (PI):  Almut G. Winterstein (10%)
Study period: 9/30/2015-9/29/2017
Funding agency: Food and Drug Administration (FDA)
This study will evaluate the effectiveness of an EHR-based algorithm that ranks patients according to hypo- and hyperglycemia risk for pharmacist intervention in two UF Health hospitals.

Quality-adjusted cost of care associated with evolution of treatment for Chronic Hepatitis C

Principal Investigator: Haesuk Park
Study Period: 07/01/2015 – 12/31/2016
Funding Agency:  Gilead Sciences, Inc.
This study is to evaluate the efficiency frontier and the quality-adjusted cost of care with evolution of treatment strategies for hepatitis C virus genotype 1 patients in the U.S.

A meta-analytic estimation of the burden of extra hepatic manifestations of hepatitis C

Principal Investigator: Haesuk Park
Study Period: 09/01/2014 – 12/31/2015
Funding Agency:  Gilead Sciences, Inc.
This study is to assess the epidemiologic burden of hepatitis C virus infection related extrahepatic manifestations.

Impact of Hepatitis C on quality-of-life: A systematic review and meta-analysis

Principal Investigator: Haesuk Park
Study Period:
 09/01/2014 – 12/31/2015
Funding Agency:  Gilead Sciences, Inc.
This study is to summarize patient-reported outcomes including health-related quality of life (HRQoL) and fatigue in hepatitis C virus infected individuals.

Impact of a telephonic outreach program on medication adherence in Medicare beneficiaries

Co-Investigator: Haesuk Park (PI: Teresa Roane)
Study Period: 10/01/2014 – 07/01/2015
Funding Agency:  Florida Department of Health
This study is to examine the impact of telephonic medication therapy management program provided by pharmacists on patients’ medication adherence.

Cost-effectiveness Analysis for Ledipasvir/Sofosbuvir for Hepatitis C Virus Infection

Principal Investigator: Haesuk Park
Study Period: 09/01/2014 – 08/01/2015
Funding Agency:  Gilead Sciences, Inc.
This study is to assess the cost-effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus (HCV) for genotype 1 treatment naïve and treatment experienced patients.

Development and validation of a complexity score to identify hospitalized patients at high risk for preventable adverse drug events

Principal Investigator: Almut G. Winterstein
Study Period: 5/1/2013-7/31/2016
Funding Agency: American Society for Health-Systems Pharmacy Research Foundation
This grant uses electronic clinical data of 13 hospitals with diverse patient populations and electronic health records to develop and validate a prospective risk scoring system that can flag hospitalized patients at risk for preventable adverse drug events.

Real-time communication of hypoglycemic risk to prioritize pharmacy medication management services

Principal investigator: Almut G. Winterstein
Study period: 7/1/2015-6/30/2016
Funding agency: UF College of Pharmacy PROSPER Excellence Award
This study will pilot the feasibility and effectiveness of an EHR-based algorithm that ranks patients according to hypoglycemia risk for pharmacist intervention.

Inpatient Psychiatric Facility Outcome and Process Measure Development and Maintenance

HHSM-500-2013-13007I [HHSM-500-T0004]
Principal investigator: Winterstein for UF/UF Health, Subcontract with Health Service Advisory Group
Study period: 9/30/2014-9/29/2018
Funding agency: Centers for Medicare and Medicaid Services
This contract will support the development and validation of eight new performance measures for inpatient psychiatric facilities along with the maintenance of existing measures.